Monti Manuela Carla, Rautio Tobias, Deventer Marie H, Schläpfer Markus, Tveit Johannes, Krotulski Alex J, Marland Victoria, Reid Robert, Daeid Niamh Nic, McKenzie Craig, Stove Christophe P, Green Henrik, Norman Caitlyn
Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.
Arch Toxicol. 2025 May 23. doi: 10.1007/s00204-025-04086-0.
An emerging new trend reveals that potent synthetic cannabinoid receptor agonists (SCRAs) that were prevalent prior to the Chinese class-wide ban in July 2021 have remained on the market or re-emerged. This is likely because of a new production route where unscheduled tail-less precursors are converted into the desired controlled SCRA via a one-step synthesis. This study reports the discovery of a clandestine production site in Switzerland for this synthesis. Controlled recreations of the synthesis of ADB-BUTINACA (also known as ADB-BINACA or ADMB-BUTINACA) and MDMB-4en-PINACA based on a recipe recovered from the Swiss production site were undertaken. The recreations yielded oils or waxy products with chromatographic purities ranging from 39.3 to 93.4% with the precursors (ADB-INACA or MDMB-INACA) remaining in all products. Mixtures of a precursor (e.g., MDMB-INACA, ADB-INACA, AB-INACA, MDMB-ICA, ADB-IATA, MDMB-5'Me-INACA) with corresponding final SCRA(s) (e.g., MDMB-4en-PINACA, 4F-MDMB-BUTINACA, MDMB-BUTINACA, MDMB-FUBINACA, ADB-BUTINACA, ADB-4en-PINACA, AB-CHMINACA, 4F-MDMB-BUTICA, ADB-FUBIATA) were found in 28 forensic casework samples in the US received between February 2023 and February 2024 and 87 samples seized from the Scottish prisons between February 2023 and July 2024. In vitro CB receptor activity of the precursors, synthesized products, and mixtures of precursors and final SCRAs were examined using β-arrestin 2 recruitment and intracellular calcium release assays. The precursors were much less potent than the final SCRAs and the concentration of the final SCRA dictated the activity of mixtures. This study raises awareness of the emergence of a new production method for SCRAs as observed in multiple countries.
一种新出现的趋势表明,在2021年7月中国全面禁令之前盛行的强效合成大麻素受体激动剂(SCRAs)仍在市场上存在或重新出现。这可能是由于一种新的生产路线,即通过一步合成将非计划的无尾前体转化为所需的受控SCRAs。本研究报告了在瑞士发现的一个用于这种合成的秘密生产地点。根据从瑞士生产地点获取的配方,对ADB-BUTINACA(也称为ADB-BINACA或ADMB-BUTINACA)和MDMB-4en-PINACA的合成进行了可控重现。重现过程产生了油状或蜡状产品,其色谱纯度在39.3%至93.4%之间,所有产品中均残留有前体(ADB-INACA或MDMB-INACA)。在美国2023年2月至2024年2月期间收到的28份法医案件样本以及2023年2月至2024年7月期间从苏格兰监狱查获的87份样本中,发现了前体(如MDMB-INACA、ADB-INACA、AB-INACA、MDMB-ICA、ADB-IATA、MDMB-5'Me-INACA)与相应最终SCRAs(如MDMB-4en-PINACA、4F-MDMB-BUTINACA、MDMB-BUTINACA、MDMB-FUBINACA、ADB-BUTINACA、ADB-4en-PINACA、AB-CHMINACA、4F-MDMB-BUTICA、ADB-FUBIATA)的混合物。使用β-抑制蛋白2募集和细胞内钙释放测定法检测了前体、合成产物以及前体与最终SCRAs混合物的体外CB受体活性。前体的效力远低于最终SCRAs,最终SCRAs的浓度决定了混合物的活性。本研究提高了对多个国家所观察到的SCRAs新生产方法出现情况的认识。